Recipient malignant hematopoietic cells

Recipient malignant hematopoietic cells refer to the population of cancerous blood-forming cells within a patient, typically in the context of hematologic malignancies such as leukemia, lymphoma, or multiple myeloma [1]. These cells are characterized by dysregulated proliferation and a failure to undergo normal differentiation, which eventually leads to the overcrowding of healthy bone marrow and systemic illness [2]. In clinical settings involving hematopoietic stem cell transplantation, these cells are the primary target of the 'graft-versus-leukemia' (GVL) effect, where donor-derived immune cells identify and eliminate residual recipient tumor cells [3]. While they are the focus of intensive therapeutic efforts, including chimeric antigen receptor (CAR) T-cell therapy and monoclonal antibodies, the term describes a broad cellular population rather than a specific molecular target like a protein or enzyme [4]. Consequently, this entry is classified as incorrect for a molecular target database as it represents a disease state or cell type rather than a single druggable molecule [5].

Other names

Malignant blood cellsLeukemic cellsCancerous hematopoietic cellsRecipient tumor cellsMalignant hematopoietic cell population

Therapeutic agents target these cells through various mechanisms including direct cytotoxicity (chemotherapy), induction of apoptosis (targeted inhibitors), or immune-mediated clearance such as the Graft-versus-Leukemia (GVL) effect or CAR-T cell recognition [3][4].